BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 17224268)

  • 1. Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families.
    Manoukian S; Peissel B; Pensotti V; Barile M; Cortesi L; Stacchiotti S; Terenziani M; Barbera F; Pasquini G; Frigerio S; Pierotti MA; Radice P; Della-Torre G
    Eur J Cancer; 2007 Feb; 43(3):601-6. PubMed ID: 17224268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.
    Varley JM; McGown G; Thorncroft M; Santibanez-Koref MF; Kelsey AM; Tricker KJ; Evans DG; Birch JM
    Cancer Res; 1997 Aug; 57(15):3245-52. PubMed ID: 9242456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.
    Lalloo F; Varley J; Moran A; Ellis D; O'dair L; Pharoah P; Antoniou A; Hartley R; Shenton A; Seal S; Bulman B; Howell A; Evans DG
    Eur J Cancer; 2006 May; 42(8):1143-50. PubMed ID: 16644204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation.
    Salmon A; Amikam D; Sodha N; Davidson S; Basel-Vanagaite L; Eeles RA; Abeliovich D; Peretz T
    Clin Oncol (R Coll Radiol); 2007 Sep; 19(7):490-3. PubMed ID: 17572079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hereditary breast cancer syndromes in a Turkish population. Results of molecular germline analysis.
    Güran S; Ozet A; Dede M; Gille JJ; Yenen MC
    Cancer Genet Cytogenet; 2005 Jul; 160(2):164-8. PubMed ID: 15993273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites.
    Rapakko K; Allinen M; Syrjäkoski K; Vahteristo P; Huusko P; Vähäkangas K; Eerola H; Kainu T; Kallioniemi OP; Nevanlinna H; Winqvist R
    Br J Cancer; 2001 Jan; 84(1):116-9. PubMed ID: 11139324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.
    Manoukian S; Peissel B; Frigerio S; Lecis D; Bartkova J; Roversi G; Radice P; Bartek J; Delia D
    Breast Cancer Res Treat; 2011 Nov; 130(1):207-15. PubMed ID: 21562711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation analysis of the CHK2 gene in families with hereditary breast cancer.
    Allinen M; Huusko P; Mäntyniemi S; Launonen V; Winqvist R
    Br J Cancer; 2001 Jul; 85(2):209-12. PubMed ID: 11461078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
    Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
    Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
    Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
    Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
    Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
    Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
    Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
    Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer.
    Campbell IG; Choong D; Chenevix-Trench G;
    Breast Cancer Res; 2004; 6(4):R366-71. PubMed ID: 15217503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations.
    Krutilkova V; Trkova M; Fleitz J; Gregor V; Novotna K; Krepelova A; Sumerauer D; Kodet R; Siruckova S; Plevova P; Bendova S; Hedvicakova P; Foreman NK; Sedlacek Z
    Eur J Cancer; 2005 Jul; 41(11):1597-603. PubMed ID: 15925506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening.
    Palomba G; Pisano M; Cossu A; Budroni M; Dedola MF; Farris A; Contu A; Baldinu P; Tanda F; Palmieri G
    Cancer; 2005 Sep; 104(6):1172-9. PubMed ID: 16047344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
    Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
    Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel TP53 germline mutation in a family with a history of multiple malignancies: case report and review of the literature.
    Agarwalla PK; Dunn IF; Turner CD; Ligon KL; Schneider KA; Smith ER
    Pediatr Neurosurg; 2008; 44(6):501-8. PubMed ID: 19127094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.